title: Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
abstract: Treatment with SQ (standardised quality) house dust mite sublingual tablet for 1 year resulted in a decreased probability of having an allergic rhinitis (AR) exacerbation day (from 11% [placebo] to 5% [SQ house dust mite sublingual tablet]) and an increased probability of having a mild AR day (from 16% [placebo] to 34% [SQ house dust mite sublingual tablet]).
authors.affiliation: Division of Allergy, Department of Pulmonology, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.|UPMC Paris 06, UMR-S 1136 INSERM, IPLESP, Equipe EPAR, Sorbonne Universités, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Demoly
authors.affiliation: Allergy & Asthma Center Westend, Outpatient Clinic & Research Center Hanf, Ackermann & Kleine-Tebbe, Berlin, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Kleine-Tebbe
authors.affiliation: ALK, Hørsholm, Denmark.
authors.forename: D
authors.initials: D
authors.lastname: Rehm
mesh_terms: D000485:Allergens / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000276:immunology*; D016022:Case-Control Studies; D006801:Humans; D016017:Odds Ratio; D039981:Pyroglyphidae / Q000276:immunology*; D065631:Rhinitis, Allergic / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D063729:Sublingual Immunotherapy / Q000009:adverse effects / Q000379:methods; D013607:Tablets; D016896:Treatment Outcome
chemical_list: D000485:Allergens; D039741:Antigens, Dermatophagoides; D013607:Tablets
keywords: SQ HDM SLIT-tablet; allergic rhinitis; allergy immunotherapy; clinical relevance; house dust mite